Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer

DR Spigel, TJ Ervin, RA Ramlau, DB Daniel… - Journal of clinical …, 2013 - ascopubs.org
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …
被引用次数：524 相关文章

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

DR Spigel, TJ Ervin, RA Ramlau… - Journal of clinical …, 2013 - profiles.wustl.edu
Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and
acquired resistance to epidermal growth factor receptor (EGFR)-targeted drugs in patients …

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

DR Spigel, TJ Ervin, DB Daniel, MS Wertheim… - Journal of Clinical …, 2013 - elibrary.ru
Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and
acquired resistance to epidermal growth factor receptor (EGFR)-targeted drugs in patients …

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

DR Spigel, TJ Ervin, RA Ramlau, DB Daniel… - Journal of Clinical …, 2013 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Increased hepatocyte growth
factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal …
[PDF] researchgate.net

[PDF][PDF] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

DR Spigel, TJ Ervin, RA Ramlau, DB Daniel… - J Clin …, 2013 - researchgate.net
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

DR Spigel, TJ Ervin, RA Ramlau, DB Daniel… - Journal of Clinical …, 2013 - europepmc.org
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)-targeted …
[PDF] psu.edu

[PDF][PDF] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

DR Spigel, TJ Ervin, RA Ramlau, DB Daniel… - J Clin Oncol, 2013 - Citeseer
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …
[HTML] nih.gov

[HTML][HTML] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

DR Spigel, TJ Ervin, RA Ramlau… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …

[引用][C] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non―Small-Cell Lung Cancer

DR SPIGEL, TJ ERVIN, R GOVINDAN… - Journal of clinical …, 2013 - pascal-francis.inist.fr
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With
Advanced Non―Small-Cell Lung Cancer CNRS Inist Pascal-Francis CNRS Pascal and …

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

DR Spigel, TJ Ervin, RA Ramlau… - Journal of clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)-targeted …